Global Bipolar Disorder Disease Market to 2024 - ResearchAndMarkets.com

September 5, 2018

DUBLIN--(BUSINESS WIRE)--Sep 5, 2018--The “Bipolar Disorder Disease Coverage to 2024” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may experience periods of mania (an overly joyful or overexcited state) followed by periods of depression (feelings of extreme sadness or hopelessness). Symptoms of bipolar disorder are severe and can result in damaged relationships, poor educational or occupational performance, and even suicide.

Market Snapshot

Temporary downturn in bipolar market value will be recouped by oral drug approvals/launches and sales momentum of LAIs. The complexity of bipolar disorder is yet to be unlocked, contributing to a lack of episode-tailored treatment strategies. Forecasted growth in the total prevalence of bipolar I disorder and bipolar II disorder will be driven by demographics. New brand Vraylar is yet to distinguish itself, but its long patent life permits ample time to improve product positioning. Otsuka initiates Phase III development of Rexulti for bipolar mania without proof-of-concept trial.

Key Topics Covered:

Forecast: Bipolar Disorder

Abilify (Aripiprazole) Abilify Maintena (Aripiprazole) Geodon (Ziprasidone) Lamictal/Lamictal Xr (Lamotrigine) Latuda (Lurasidone) Lumateperone Risperdal Consta (Risperidone) Saphris (Asenapine) Seroquel/Seroquel Xr (Quetiapine) Vraylar (Cariprazine) Zyprexa (Olanzapine)

Treatment: Bipolar Disorder

Primary Research Methodology Disease Definition And Diagnosis Patient Segmentation Current Treatment Options Treatment Dynamics Unmet Needs In Bipolar Disorder

Epidemiology: Bipolar Disorder In The US, Japan, And 5EU

Disease Background Sources And Methodology Forecast: Bipolar I Disorder Forecast: Bipolar Ii Disorder Epidemiologist Insight Strengths And Limitations

Marketed Drugs: Bipolar Disorder

Product Profile: Abilify Product Profile: Abilify Maintena Product Profile: Geodon Product Profile: Lamictal Product Profile: Latuda Product Profile: Risperdal Consta Product Profile: Saphris Product Profile: Seroquel/Seroquel Xr Product Profile: Vraylar Product Profile: Zyprexa

Pipeline: Bipolar Disorder

Clinical Pipeline Overview Product Profile (Late Stage): Alks 3831 Product Profile (Late Stage): Rexulti Product Profile (Late Stage): Lumateperone

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6gc3z6/global_bipolar?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005449/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Health



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/05/2018 06:45 AM/DISC: 09/05/2018 06:45 AM


Update hourly